1. Abstracts from the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014. Issue 5 (May 2015) Authors: Zwarthoed, Cholette; Ouvier, Matthieu John; Borra, Anna; Bergesio, Fabrizio; Chauvie, Stephane; Biggi, Alberto; Hutchings, Martin; El-Galaly, Tarek; Gallamini, Andrea; Simon, Zsófia; Miltényi, Zsófia; Magyari, Ferenc; Barna, Sándor; Kenyeres, Anna; Jóna, Ádám; Illés, Árpád; Dann, Eldad J.; Bar-Sh... Journal: Leukemia & lymphoma Issue: Volume 56:Issue 5(2015:May) Page Start: 1233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Issue 3 (March 2017) Authors: Zelenetz, Andrew D; Barrientos, Jacqueline C; Brown, Jennifer R; Coiffier, Bertrand; Delgado, Julio; Egyed, Miklós; Ghia, Paolo; Illés, Árpád; Jurczak, Wojciech; Marlton, Paula; Montillo, Marco; Morschhauser, Franck; Pristupa, Alexander S; Robak, Tadeusz; Sharman, Jeff P; Simpson, David; Smolej, ... Journal: Lancet oncology Issue: Volume 18:Issue 3(2017:Mar.) Page Start: 297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Issue 7 (July 2019) Authors: Soumerai, Jacob D; Ni, Ai; Darif, Mohamed; Londhe, Anil; Xing, Guan; Mun, Yong; Kay, Neil E; Shanafelt, Tait D; Rabe, Kari G; Byrd, John C; Chanan-Khan, Asher A; Furman, Richard R; Hillmen, Peter; Jones, Jeffrey; Seymour, John F; Sharman, Jeffrey P; Ferrante, Lucille; Mobasher, Mehrdad; Stark, Th... Journal: Lancet Issue: Volume 6:Issue 7(2019) Page Start: e366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Issue 8 (August 2022) Authors: Pagel, John M; Soumerai, Jacob D; Reddy, Nishitha; Jagadeesh, Deepa; Stathis, Anastasios; Asch, Adam; Salman, Huda; Kenkre, Vaishalee P; Iasonos, Alexia; Llorin-Sangalang, Judith; Li, Joanne; Zelenetz, Andrew D Journal: Lancet oncology Issue: Volume 23:Issue 8(2022) Page Start: 1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Issue 12 (December 2021) Authors: Soumerai, Jacob D; Mato, Anthony R; Dogan, Ahmet; Seshan, Venkatraman E; Joffe, Erel; Flaherty, Kelsey; Carter, Jason; Hochberg, Ephraim; Barnes, Jeffrey A; Hamilton, Audrey M; Abramson, Jeremy S; Batlevi, Connie L; Matasar, Matthew J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Kumar, Anita; ... Journal: Lancet Issue: Volume 8:Issue 12(2021) Page Start: e879 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗